Cáncer renal

  1. Peñas Pita da Veiga, M. 1
  2. Nalda Arija, I. 1
  3. Bernier García, L. 1
  4. Chara Velarde, L. 1
  5. Cassinello Espinosa, J. 1
  1. 1 Unidad de Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, España
Revista:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Año de publicación: 2021

Título del ejemplar: Enfermedades oncológicas (III) Tumores genitourinarios

Serie: 13

Número: 26

Páginas: 1431-1440

Tipo: Artículo

DOI: 10.1016/J.MED.2021.02.011 DIALNET GOOGLE SCHOLAR

Otras publicaciones en: Medicine: Programa de Formación Médica Continuada Acreditado

Resumen

El cáncer de riñón es la séptima neoplasia en frecuencia y es más frecuente en varones. Se desconoce la etiología exacta de esta enfermedad, aunque se ha podido establecer su relación con el tabaco o la obesidad. Un 2% son hereditarios, asociados a síndromes genéticos, como la enfermedad de von Hippel-Lindau. En el 50% de los casos se diagnostican como incidentalomas al realizar pruebas de imagen por otros motivos. El cáncer renal de células claras es la histología más frecuente. Se estadifica según el sistema TNM de la AJCC y en base a la evaluación del riesgo (bajo, intermedio o alto según la escala del MSKCC). El tratamiento del carcinoma renal localizado es eminentemente quirúrgico y, en base a los estudios actuales, no hay evidencia para la adyuvancia. El tratamiento de la enfermedad avanzada se basa en el empleo de la inmunoterapia y los inhibidores de la tirosinquinasa (TKI) según el grupo de riesgo de cada paciente.

Referencias bibliográficas

  • Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guide-lines for diagnosis, treatment and follow-up. Ann Oncol. 2019;30: 706-20.
  • Cumberbatch MG, Rota M, Catto JW, La Vecchia C. The role of tobacco smoke in bladder and kidney carcinogenesis: a comparison of exposures and meta-analysis of incidence and mortality risks. Eur Urol. 2016;70(3): 458-66.
  • Wu X, Shu X. Epidemiology of renal cell carcinoma. En: Oya M, editor. Renal cell carcinoma. Japan: Springer; 2017. p. 1-18.
  • McLaughlin JK, Lipworth L. Epidemiological aspects of renal cancer. Semin Oncol. 2006;33:527-33.
  • Salinas Vert I, Oriola Ambros J. La enfermedad de von Hippel-Lindau. Endocrinol Nutr. 1999;46(2):68.
  • Baba M, Schmidt L, Linehan W. Hereditary renal cell carcinoma. En: Oya M, editor. Renal cell carcinoma. Japan: Springer; 2017. p. 19-82
  • Turajlic S, Swanton C, Boshoff C. Kidney cancer: The next decade. J Exp Med. 2018;215(10):2477-9.
  • Sanz-Ortega J, Olivier C, Pérez Segura P, Galante Romo I, San José Man-só L, Saez M. Cáncer de riñón hereditario [Hereditary renal cancer]. Actas Urol Esp. 2009;33(2):127-33.
  • Sobin LH. The international histological classification of tu-mours. Bull World Health Organ. 1981;59(6):813-9.
  • Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93-105.
  • Mehdi A, Riazalhosseini Y. Epigenome aberrations: emerging driving fac-tors of the clear cell renal cell carcinoma. Int J Mol Sci. 2017;18(8):1774.
  • Argani P, Reuter VE, Zhang L, Sung YS, Ning Y, Epstein JI, et al. TFEB-amplified renal cell carcinomas: an aggressive molecular subset demonstrating variable melanocytic marker expression and morphologic hetero-geneity. Am J Surg Pathol. 2016;40(11):1484-95.
  • Cancer genome atlas research network, Linehan WM, Spellman PT, Ric-ketts CJ, et al. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 2016;374(2):135-45.
  • Liu L, Qian J, Singh H, Meiers I, Zho, Meiers I, Zhou X, Bostwick DG. Immunohistochemical analysis of chromophobe renal cell carcinoma, renal oncocytoma, and clear cell carcinoma: an optimal and practical panel for differential diagnosis. Arch Pathol Lab Med. 2007;131:1290-7.
  • Fukawa T, Shannon N, Huang D, et al. Molecular genetics of renal cell carcinoma. En: Oya, editor M. Renal cell carcinoma. Japan: Springer; 2017. p. 83-103.
  • Correa A, Lane B, Rini B, Uzzo R. Cancer of the kidney. En: De Vita VT, Lawrence TS, Rosemberg SA, editors. Cancer principles and practice of oncology. 11th ed. New York: Wolters Kluwer; 2019. p. 1020-41.
  • Puga M, González-Ballina E, Rivas-Moral L. Stauffer’s syndrome variant as an unusual case of painless jaundice. Clin Gastroenterol Hepatol. 2015;13(9):25-6.
  • Lazaro M, Valderrama BP, Suárez C, de Velasco G, Beato C, Chirivella I, et al. SEOM Guidelines of renal cancer. Clin Transl Oncol. 2020; 22:256-69.
  • Swami U, Nussenzveig RH, Haaland B, Agarwal N. Revisiting AJCC TNM staging for renal cell carcinoma: quest for improvement. Ann Transl Med. 2019;7Suppl1:S18.
  • Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:5794-9.
  • Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-63.
  • Brooks SA, Brannon AR, Parker JS, Fisher JC, Sen O, Kattan MW, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol. 2014;66(1): 77-84.
  • MacLennan S, Imamura M, Lapitan MC, Omar MI, Lam TB, Hilvano-Ca-bungcal AM, et al. Systematic review of oncological outcomes following surgical management of localized renal cancer. Eur Urol. 2012;61(5):972-93.
  • Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, et al. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): adouble-blind, placebo-controlled, randomised, phase 3 trial. Lancet. 2016;387(10032):2008.
  • Motzer RJ, Haas NB, Donskov F, Gross-Goupil M, Varlamov S, Kopylts-ov E, et al. Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma. J Clin Oncol. 2017;35:3916-23.
  • Gross-Goupil M, Kwon TG, Eto M, Ye D, Miyake H, Seo SI, et al. Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial. Ann Oncol. 2018;29:2371-8.
  • Blinman PL, Davis ID, Martin A, Troon S, Sengupta S, Hovey E, et al. Patients’ preferences for adjuvant sorafenib after resection of renal cell carcinoma in the SORCE trial: what makes it worthwhile? Ann Oncol. 2018;29:370-6.
  • Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246-54.
  • Me ́jean A, Ravaud A, Thezenas S, Colas S, Beauval JB, Bensalah K, et al. Sunitinib alone or after nephrectomy in metastatic renal-cell carcinoma. N Engl JMed. 2018;379:417-27.
  • Bex A, Mulders P, Jewett M, Wagstaff J, van Thienen JV, Blank CU, et al. Comparison of immediate vs deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial. JAMA Oncol. 2019;5:164-70.
  • Motzer RJ, RussoP. Systemic therapy for renal cell carcinoma. J Urol. 2000;163:408-17.
  • Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
  • Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722-31.
  • Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind pha-se III trial. Lancet. 2007;370:2103-11.
  • Motzer R.J, Nosov D, Eisen T, Bondarenko I, Lesovoy V, Lipa-tov O, et al. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial. J Clin Oncol. 2013; 31: 3791-9.
  • Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1116-27.
  • Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Me-lichar B, Choueiri TK, et al. Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med. 2018;378: 1277-90.
  • Motzer RJ, Penkov K, Haanen J, Rini B, Albiges L, Campbell MT, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380:1103-15.
  • Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Sua-rez C, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. The Lancet. 2019;393:2404-15.
  • Choueiri TK, Powles T, Burotto M, Haanen J, Campbell MT, Venugopal B, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol. 2020;31(8):1030-9.
  • Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803-13.
  • Choueiri TK, Escudier B, Powles T, Mainwaring PN, Rini BI, Donskov F, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1814-23.
  • Choueiri TK, Escudier B, Powles T, Tannir NM, Mainwaring PN, Rini BI, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17:917-27.
  • Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Ei-sen T, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473-82.
  • Motzer RJ, Porta C, Vogelzang NJ, Sternberg CN, Szczylik C, Zolnierek J, et al. Dovitinib versus sorafenib for third line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomized phase 3 trial. Lancet Oncol. 2014;15:286-96.
  • Armstrong AJ, Halabi S, Eisen T, Broderick S, Stadler WM, Jones RJ, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lancet Oncol. 2016;17:378-88.
  • Tannir NM, Jonasch E, Albiges L, Altinmakas E, Ng CS, Matin SF, et al. Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol. 2016;69:866-74
Fuente de los datos: Dialnet